share_log

藥明康德:海外監管公告

WUXI APPTEC: Overseas Regulatory Notice

HKEX ·  Jul 29 08:26
Summary by Moomoo AI
無錫藥明康德於2024年7月29日宣布,根據其2019年限制性股票與股票期權激勵計劃,公司已同意注銷7名激勵對象因離職或未在行權期內行權而未行使的股票期權共計31,509份。此次注銷行動已經過董事會和監事會的審議通過,並符合相關法律法規及激勵計劃的規定。上海市方達(北京)律師事務所對此次注銷事宜出具了法律意見書,確認注銷程序和數量合法有效,並無損害公司及全體股東利益的行為。
無錫藥明康德於2024年7月29日宣布,根據其2019年限制性股票與股票期權激勵計劃,公司已同意注銷7名激勵對象因離職或未在行權期內行權而未行使的股票期權共計31,509份。此次注銷行動已經過董事會和監事會的審議通過,並符合相關法律法規及激勵計劃的規定。上海市方達(北京)律師事務所對此次注銷事宜出具了法律意見書,確認注銷程序和數量合法有效,並無損害公司及全體股東利益的行為。
Wuxi AppTec announced on July 29, 2024 that, under its 2019 Restricted Stock and Stock Option Incentive Plan, the company had agreed to cancel a total of 31,509 stock options that had been granted to 7 incentive recipients who had left the company or failed to exercise the options during the exercise period. The cancellation has been approved by the Board of Directors and the Supervisory Board and is in compliance with relevant laws and regulations as well as the Incentive Plan. Fangda Partners (Beijing) Law Firm has issued a legal opinion on the cancellation, confirming that the cancellation procedures and quantity are legal and effective, and that the act does not harm the interests of the company and all shareholders.
Wuxi AppTec announced on July 29, 2024 that, under its 2019 Restricted Stock and Stock Option Incentive Plan, the company had agreed to cancel a total of 31,509 stock options that had been granted to 7 incentive recipients who had left the company or failed to exercise the options during the exercise period. The cancellation has been approved by the Board of Directors and the Supervisory Board and is in compliance with relevant laws and regulations as well as the Incentive Plan. Fangda Partners (Beijing) Law Firm has issued a legal opinion on the cancellation, confirming that the cancellation procedures and quantity are legal and effective, and that the act does not harm the interests of the company and all shareholders.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more